ArticlePharmaceutics2021
Silk Fibroin Microneedle Patches for the Treatment of Insomnia.
Article in Pharmaceutics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 34 citations in OpenAlex.
- Overcoming Biological Barriers: A Comprehensive Review of Advanced Melatonin Delivery Systems for Therapeutic Applications.International journal of medical sciences · 2026Review
- Progressive microneedles for targeting and intelligent drug delivery.Asian journal of pharmaceutical sciences · 2025Review
- Ultrasonication-Induced Preparation of High-Mechanical-Strength Microneedles Using Stable Silk Fibroin.Polymers · 2024Article
- A flexible and dissolving traditional Chinese medicine microneedle patch for sleep-aid intervention.Heliyon · 2024Article
- The Emerging Role of Silk Fibroin for the Development of Novel Drug Delivery Systems.Biomimetics (Basel, Switzerland) · 2024Review
- Digital automation of transdermal drug delivery with high spatiotemporal resolution.Nature communications · 2024Article
- Controlled release of bilayer tablet comprising vitamin BPharmaceutical science advances · 2023Article
- Triptorelin nanoparticle-loaded microneedles for use in assisted reproductive technology.Drug delivery · 2023Article
- Clinical Spectrum and Trajectory of Innovative Therapeutic Interventions for Insomnia: A Perspective.Aging and disease · 2023Article
- A Sustainable Solution to Skin Diseases: Ecofriendly Transdermal Patches.Pharmaceutics · 2023Review
- Glucose-Responsive Silk Fibroin Microneedles for Transdermal Delivery of Insulin.Biomimetics (Basel, Switzerland) · 2023Article
- Silk Fibroin Microneedles for Transdermal Drug Delivery: Where Do We Stand and How Far Can We Proceed?Pharmaceutics · 2023Review
- Sericultural By-Products: The Potential for Alternative Therapy in Cancer Drug Design.Molecules (Basel, Switzerland) · 2023Review
- Silk fibroin carriers with sustained release capacity for treating neurological diseases.Frontiers in pharmacology · 2023Review
- Research progress of natural silk fibroin and the application for drug delivery in chemotherapies.Frontiers in pharmacology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 2 countries.
Funding
Abstract
As a patient-friendly technology, drug-loaded microneedles can deliver drugs through the skin into the body. This system has broad application prospects and is receiving wide attention. Based on the knowledge acquired in this work, we successfully developed a melatonin-loaded microneedle prepared from proline/melatonin/silk fibroin. The engineered microneedles' morphological, physical, and chemical properties were characterized to investigate their structural transformation mechanism and transdermal drug-delivery capabilities. The results indicated that the crystal structure of silk fibroin in drug-loaded microneedles was mainly Silk I crystal structure, with a low dissolution rate and suitable swelling property. Melatonin-loaded microneedles showed high mechanical properties, and the breaking strength of a single needle was 1.2 N, which could easily be penetrated the skin. The drug release results in vitro revealed that the effective drug concentration was obtained quickly during the early delivery. The successful drug concentration was maintained through continuous release at the later stage. For in vivo experimentation, the Sprague Dawley (SD) rat model of insomnia was constructed. The outcome exhibited that the melatonin-loaded microneedle released the drug into the body through the skin and maintained a high blood concentration (over 5 ng/mL) for 4-6 h. The maximum blood concentration was above 10 ng/mL, and the peak time was 0.31 h. This system indicates that it achieved the purpose of mimicking physiological release and treating insomnia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.